News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
138,352 Results
Type
Article (6176)
Company Profile (11)
Press Release (132164)
Multimedia
Podcasts (27)
Webinars (1)
Section
Business (50098)
Career Advice (165)
Deals (7951)
Drug Delivery (36)
Drug Development (16991)
Employer Resources (15)
FDA (3020)
Job Trends (3603)
News (71118)
Policy (5171)
Tag
2027 Pharm Country Standard (1)
Academia (471)
Accelerated approval (22)
ADA (12)
Adcomms (4)
Allergies (54)
Alliances (5562)
ALS (55)
Alzheimer's disease (440)
Antibody-drug conjugate (ADC) (142)
Approvals (3306)
Artificial intelligence (104)
ASCO (88)
Autoimmune disease (99)
Automation (4)
Bankruptcy (67)
Belgium (1)
Best Places to Work (3191)
BIO (5)
Biologics (3)
BIOSECURE Act (2)
Biosimilars (70)
BioSpace Insights (16)
Biotechnology (11)
Bladder cancer (79)
Brain cancer (26)
Breast cancer (271)
Cancer (1900)
Cardiovascular disease (180)
Career advice (155)
Career pathing (6)
CAR-T (74)
CDC (8)
CDMO (26)
Celiac Disease (1)
Cell therapy (210)
Cervical cancer (13)
Clinical research (16207)
Collaboration (363)
Commercialization (2)
Company closure (2)
Compensation (253)
Complete response letters (12)
COVID-19 (502)
CRISPR (27)
C-suite (148)
Cystic fibrosis (25)
Data (2957)
Decentralized trials (1)
Denatured (4)
Depression (40)
Dermatology (48)
Diabetes (189)
Diagnostics (1466)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (6)
Drug discovery (69)
Drug pricing (56)
Duchenne muscular dystrophy (58)
Earnings (37154)
Editorial (19)
Employer branding (3)
Employer resources (14)
Events (23523)
Executive appointments (126)
FDA (4228)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (8)
Frontotemporal dementia (12)
Funding (291)
Gene editing (53)
Generative AI (10)
Gene therapy (191)
GLP-1 (325)
Government (826)
Grass and pollen (1)
Guidances (326)
Healthcare (4234)
Hematology (59)
HIV (48)
Huntington's disease (40)
IgA nephropathy (31)
Immunology and inflammation (91)
Immuno-oncology (30)
Indications (75)
Infectious disease (598)
Inflammatory bowel disease (62)
Inflation Reduction Act (4)
Influenza (36)
Intellectual property (45)
Interviews (20)
IPO (5100)
IRA (16)
Job creations (573)
Job search strategy (135)
JPM (11)
Kidney cancer (4)
Labor market (31)
Layoffs (125)
Leadership (5)
Legal (909)
Licensing (5)
Liver cancer (27)
Longevity (4)
Lung cancer (312)
Lymphoma (188)
Machine learning (7)
Management (4)
Manufacturing (188)
Marketing (3)
MASH (61)
Medical affairs (1)
Medical device (3073)
Medtech (3118)
Mergers & acquisitions (3170)
Metabolic disorders (503)
mRNA (41)
Multiple sclerosis (42)
NASH (6)
Netherlands (2)
Neurodegenerative disease (121)
Neuropsychiatric disorders (31)
Neuroscience (850)
NextGen: Class of 2026 (1176)
Non-profit (914)
Now hiring (7)
Obesity (239)
Opinion (40)
Ovarian cancer (78)
Pain (34)
Pancreatic cancer (128)
Parkinson's disease (74)
Partnered (3)
Patents (77)
Patient recruitment (136)
Peanut (8)
People (6224)
Pharmaceutical (5)
Pharmacy benefit managers (7)
Phase 1 (4215)
Phase 2 (6809)
Phase 3 (6589)
Pipeline (4487)
Policy (64)
Postmarket research (619)
Preclinical (1365)
Press Release (13)
Prostate cancer (90)
Psychedelics (15)
Radiopharmaceuticals (71)
Rare diseases (250)
Real estate (763)
Recruiting (5)
Regulatory (4798)
Reports (23)
Research institute (421)
Resumes & cover letters (13)
Rett syndrome (12)
RNA editing (10)
RSV (30)
Schizophrenia (54)
Series A (48)
Series B (41)
Sickle cell disease (27)
Special edition (11)
Spinal muscular atrophy (28)
Sponsored (8)
Startups (420)
Stomach cancer (1)
Supply chain (20)
Tariffs (22)
The Weekly (23)
Vaccines (253)
Venture capital (22)
Weight loss (176)
Women's health (26)
Worklife (5)
Date
Today (26)
Last 7 days (96)
Last 30 days (569)
Last 365 days (7985)
2026 (5688)
2025 (7999)
2024 (8604)
2023 (9143)
2022 (11468)
2021 (12406)
2020 (11862)
2019 (9691)
2018 (7151)
2017 (6009)
2016 (4890)
2015 (6276)
2014 (4877)
2013 (3453)
2012 (3981)
2011 (4075)
2010 (3711)
Location
Africa (147)
Alabama (19)
Arizona (57)
Arkansas (4)
Asia (8317)
Australia (1157)
California (3903)
Canada (1048)
China (425)
Colorado (159)
Connecticut (179)
Delaware (154)
Europe (19602)
Florida (503)
Georgia (110)
Hawaii (2)
Idaho (6)
Illinois (354)
India (16)
Indiana (231)
Iowa (3)
Japan (214)
Kansas (28)
Kentucky (10)
Louisiana (16)
Maine (30)
Maryland (394)
Massachusetts (2570)
Michigan (81)
Minnesota (205)
Mississippi (2)
Missouri (27)
Montana (6)
Nebraska (5)
Nevada (38)
New Hampshire (21)
New Jersey (1498)
New Mexico (4)
New York (1046)
North Carolina (442)
North Dakota (2)
Northern California (2105)
Ohio (97)
Oklahoma (2)
Oregon (5)
Pennsylvania (749)
Puerto Rico (5)
Rhode Island (6)
South America (208)
South Carolina (11)
South Dakota (1)
Southern California (1558)
Tennessee (51)
Texas (559)
United States (13580)
Utah (100)
Virginia (68)
Washington D.C. (7)
Washington State (283)
Wisconsin (22)
138,352 Results for "13".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.
May 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - August 13, 2026
August 14, 2026
·
4 min read
Press Releases
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
July 30, 2026
·
1 min read
Press Releases
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
August 6, 2026
·
1 min read
Press Releases
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
July 30, 2026
·
1 min read
Press Releases
Radioligand Therapy (RLT) Market Worth $10.91 Billion by 2035, Growing at 13.2% CAGR
June 1, 2026
·
1 min read
Press Releases
Novo Nordisk A/S - share repurchase programme - July 13, 2026
July 13, 2026
·
2 min read
Press Releases
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
July 30, 2026
·
1 min read
Press Releases
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
August 5, 2026
·
1 min read
Deals
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
For $110 million upfront, GSK will have the exclusive global right to advance HMPL-A830, which combines an EGFR-targeting antibody with a small-molecule KRAS blocker. The asset will be studied for colorectal, pancreatic and lung cancer.
September 3, 2026
·
1 min read
·
Tristan Manalac
1 of 13,836
Next
